Cummings, Matthew J. http://orcid.org/0000-0003-2906-0966
Bakamutumaho, Barnabas
Lutwama, Julius J.
Owor, Nicholas
Che, Xiaoyu
Astorkia, Maider
Postler, Thomas S. http://orcid.org/0000-0002-3558-9084
Kayiwa, John
Kiconco, Jocelyn
Muwanga, Moses
Nsereko, Christopher
Rwamutwe, Emmanuel
Nayiga, Irene
Kyebambe, Stephen
Haumba, Mercy
Bosa, Henry Kyobe http://orcid.org/0000-0001-6593-8727
Ocom, Felix
Watyaba, Benjamin http://orcid.org/0000-0003-2512-8425
Kikaire, Bernard http://orcid.org/0000-0001-9478-9062
Tomoiaga, Alin S.
Kisaka, Stevens
Kiwanuka, Noah
Lipkin, W. Ian http://orcid.org/0000-0002-8768-9386
O’Donnell, Max R.
Watyaba, Benjamin
Kikaire, Bernard
O’Donnell, Max R.
,
Funding for this research was provided by:
U.S. Department of Health Human Services | NIH | National Institute of Allergy and Infectious Diseases (K23AI163364)
U.S. Department of Health Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21AI171249)
Burroughs Wellcome Fund (N/A)
U.S. Department of Health Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001873)
Article History
Received: 25 April 2023
Accepted: 17 January 2024
First Online: 17 February 2024
Competing interests
: M.J.C. and M.R.O’D. were investigators for clinical trials evaluating the efficacy and safety of remdesivir, convalescent plasma, and anti-SARS-CoV-2 hyperimmune globulin in hospitalized patients with COVID-19, sponsored by Gilead Sciences, Amazon, and the National Institutes of Health, respectively. Compensation for this work was paid to Columbia University. The remaining authors declare no competing interests.
: Each enrolled participant or their surrogate provided written informed consent. Study protocols were approved by ethics committees at Columbia University (AAAR1450), Uganda Virus Research Institute (GC/127/17/02-06/582), and Uganda National Council for Science and Technology (HS2308).